click on circles to display study description...
atezolizumab alone (n=54) vs. sunitinib (n=60)
randomized controlled trial
atezolizumab
atezolizumab 1,200mg fixed intravenous dose every three weeks
sunitinib
sunitinib 50mg/d orally for four weeks followed by two weeks of rest
3 bras : atezolizumab, atezolizumab and bevacizumab, sunitinibpatients randomized to atezolizumab monotherapy or sunitinib had the option to cross over and receive the atezolizumab bevacizumab combination in some regions
mRCC - L1 - PDL1 positive
patietns had a Karnofsky performance score ≥ 70, . Patients were required to have adequate hematologic and end-organ function.
open-label
96 institution
P2/interim analysis planned but no treshhold, no stratistic plan found (no protocol)
Overall, data from IMmotion150 suggest (did not demonstrare PFS benefit) that atezolizumab plus bevacizumab may particularly enhance PFS benefit in patients with pre-existing antitumor immunity (as determined by a high Teff score and PD-L1 IC expression) compared with sunitinib
atezolizumab plus bevacizumab (n=178) vs. sunitinib (n=184)
randomized controlled trial
atezolizumab plus bevacizumab
atezolizumab 1200 mg intravenously then bevacizumab 15 mg/kg intravenous infusions once every 3 weeks.
Sunitinib
sunitinib 50 mg once daily orally for 4 weeks, followed by 2 weeks of rest
No prespecified crossover was planned per protocol. Patients could continue atezolizumab plus bevacizumab or sunitinib
mRCC - L1 - PDL1 positive
Patients were excluded if they had received previous systemic treatment or if they had untreated brain metastases.
open label
152 sites across 21 countries
P3 / two-sided test procedure with two interim analysis. AI 1 (12 months) repartition between coprmary endpoints (0.04 PFS and 0.01 OS) and then hierarchy with OS (PDL1>1%)
Atezolizumab plus bevacizumab did not significantly prolonged progression-free survival versus sunitinib in patients with metastatic renal cell carcinoma but showed a favourable safety profile. exploratory results for this arm
atezolizumab plus bevacizumab (n=50) vs. sunitinib (n=60)
randomized controlled trial
atezolizumab with bevacizumab
atezolizumab 1,200mg fixed intravenous dose bevacizumab 15mg/kg every three weeks
sunitinib
sunitinib 50mg/d orally for four weeks followed by two weeks of rest
3 bras : atezolizumab, atezolizumab and bevacizumab, sunitinibpatients randomized to atezolizumab monotherapy or sunitinib had the option to cross over and receive the atezolizumab bevacizumab combination in some regions
mRCC - L1 - PDL1 positive
they had a Karnofsky performance score ≥ 70, . Patients were required to have adequate hematologic and end-organ function.
open-label
96 institution
P2/interim analysis planned but no treshhold, no stratistic plan found (no protocol)
Overall, data from IMmotion150 suggest (did not demonstrare PFS benefit) that atezolizumab plus bevacizumab may particularly enhance PFS benefit in patients with pre-existing antitumor immunity (as determined by a high Teff score and PD-L1 IC expression) compared with sunitinib
avelumab plus axitinib (n=270) vs. sunitinib (n=290)
randomized controlled trial
Avelumab plus Axitinib
Avelumab was administered at a dose of 10 mg per kilogram of body weight as a 1-hour intravenous infusion every 2 weeks, Axitinib was administered orally at a starting dose of 5 mg twice daily on a continuous dosing schedule.An antihistamine and acetaminophen were administered approximately 30 to 60 minutes before each infusion.
Sunitinib
Sunitinib was administered at a dose of 50 mg orally once daily for 4 weeks of an 6-week cycle.
Dose reductions of avelumab were not permitted, but subsequent infusions could be omitted in response to persisting toxic effects. Dose escalations and reductions of axitinib and dose reductions of sunitinib are described in the protocol
mRCC - L1 - PDL1 positive
patients with IMDC and MSKCC prognostic risk groups were included.Key exclusioncriteria included active central nervous system metastases
open label
144 sites in 21 countries
P3 /one sided test procedure with one interim analysis . Repartition between coprimary endpoints (0.004/0.021) and hierarchical testing procedure with secondary endpoints
Progression-free survival was significantly longer with avelumab plus axitinib than withsunitinib among patients who received these agents as first-line treatment for advancedrenal-cell carcinoma (ITT and PDL1>1%)
powered by vis.js Network